
















DRAMATIC REBOUNDS OF MS DURING
PREGNANCY FOLLOWING FINGOLIMOD
WITHDRAWAL
In MS, discontinuation of some therapies may result
in a transitory, possibly overwhelming, increase in
disease activity.1–4 We report 2 cases of severe clinical
rebound after fingolimod suspension occurring in 2
patients following pregnancy. Clinical rebound was
defined as the occurrence of new severe neurologic
symptoms together with a significant increase of new
or enlarging T2-weighted or gadolinium-enhancing
T1-weighted lesions exceeding baseline activity, on
treatment discontinuation.4 The first patient was
diagnosed with MS in 2005. In the subsequent 3
years, she experienced several relapses and progressive
increase of MRI lesion load despite the sequential
introduction of weekly interferon-b1a, thrice weekly
interferon-b1a and then glatiramer acetate. Natalizu-
mab (NTZ) was then started (EDSS 3.0, JCV anti-
bodies negative status), resulting in no evidence of
disease activity for the following 40 months. On sero-
conversion, NTZ was interrupted in August 2011
beacause of the potential risk of progressive multifocal
leukoencephalopathy (PML) and fingolimod was
started. In March 2013, fingolimod was suspended
as disease was stable (figure, A) and due to desire of
pregnancy and potential risks of fetal exposure to
fingolimod.5 Lymphocyte count was 0.34 3 109/L.
In April 2013, she resulted pregnant. In July (elev-
enth week of pregnancy), she abruptly developed
quadriplegia and signs of severe cognitive impairment
(EDSS: 9.0). Lymphocyte count was 1.54 3 109/L.
One gram of methylprednisolone was administered
IV for 5 days with partial recovery (EDSS 7.0).
One month later, she developed locked-in syndrome
(EDSS 9.5). Brain MRI showed a dramatic increase
of white-matter abnormalities with many
gadolinium-enhancing lesions (figure, B). PML was
excluded by CSF analysis. IV methylprednisolone
followed by IV immunoglobulins were administered
with no success. Plasma exchange was not considered
because of the possible adverse effects on maternal
hemodynamics and limited experience on pregnant
patients with MS. On therapeutic abortion, she
received IV cyclophosphamide (2 g/m2), improving
clinically (EDSS 7.0) and radiologically (figure, C).
One month later, her clinical condition deteriorated
(EDSS 8.0) with worsening of brain MRI (figure, D).
She was treated again with IV cyclophosphamide
(1 g/m2), but a few days later, she developed septic
shock and died.
The second patient was diagnosed with MS in
1995 and was treated from 1999, first with inter-
feron-b1a once weekly, then interferon-b1a 22 mcg
3 times weekly and subsequently interferon-b1a 44
mcg 3 times weekly. In 2004, because of insufficient
disease control, she received 4 infusions with mitox-
antrone 12 mg/m2 monthly followed by interferon-
b1b. In May 2005, interferon-b1b was suspended
when the patient resulted pregnant. In 2006, follow-
ing childbirth, she started azathioprine and after a few
months, because of disease progression, she was
infused with 4 additional doses of mitoxantrone. In
2007, she started NTZ with no signs of disease activ-
ity for 28 months. In October 2010, NTZ was sus-
pended fearing PML. In June 2011, she started
fingolimod with incomplete disease control. In Sep-
tember 2014 (EDSS 3.0), she was again pregnant and
therapy was suspended. Lymphocyte count was 0.73
109/L. Four weeks later, with a lymphocyte count of
2 3 109/L, she experienced severe left leg monopa-
resis and dysarthria (EDSS 6.0). IV methylpredniso-
lone was administered with no results. Four weeks
later, therapeutic abortion was performed. One week
later, she presented with tetraplegia and anarthria
(EDSS 9.5). She received high-dose steroids, followed
by plasma-exchange and rituximab (two 1-g infusions
15 days apart) with radiologic and clinical improve-
ment (EDSS 5.5 on April 2015). In May 2015,
dimethyl fumarate was started with slow progression
to EDSS 6.5 (January 2017).
Suspension of therapies affecting lymphocytes
trafficking to the CNS, such as NTZ and fingolimod,
may rarely result in disease rebound. Compared with
dramatic deterioration of disease following NTZ sus-
pension, fingolimod withdrawal usually results in
mild disease recrudescence,3,4 mostly controlled by
steroids. In the reported cases, rebound after fingoli-
mod suspension was rapidly devastating despite
occurring during the early phase of pregnancy, a con-
dition associated with a significant reduction of
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relapse risk. Possibly, abortion may have led to hor-
monal changes contributing to increasing disease
activity similarly to what was observed in the post-
partum.
Thus, we suggest that similar to current protocols
adopted for NTZ discontinuation, fingolimod sus-
pension in patients with high-disease activity during
previous treatments should be carefully monitored
to detect early signs of disease reactivation poten-
tially requiring immediate highly effective treat-
ments. Moreover, early lymphocytes levels increase
after fingolimod cessation could represent a warning
sign possibly associated with their migration to the
CNS.6 Whether these rare events are due to a possi-
ble change in the expression of key S1P receptors on
immune or CNS target cells will require further
studies.7 The possible outcome following therapy
discontinuation should be carefully considered at
the time of treatment choice in young women in
child-bearing age, who need to be properly advised
of possible risks of rapid disease worsening after
treatment suspension.
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Figure Patient 1 MRI scans
(A) Brain MRI performed on October 12, 2012. (A.a) FLAIR (FLuid Attenuated Inversion Recovery) sequence. (A.b) T1 gadolinium enhanced sequence. Routine
MRI scan during fingolimod therapy shows some periventricular juxtacortical FLAIR white-matter hyperintensities with no gadolinium enhanced lesions. (B)
Brain MRI performed on August 29, 2013. In the FLAIR sequence diffuse and confluent white-matter hyperintensities are found in both hemispheres in the
periventricular and subcortical white matter, with the involvement of the “U” fibers. Many lesions show gadolinium enhancement. (C) Brain MRI performed on
October 17, 2013. One month after cyclophosphamide IV administration. FLAIR white-matter hyperintensities are significantly reduced (C.a) and no lesion
display gadolinium enhancement (C.b) compared with the MRI performed on 29th of August (B). (D) Brain MRI performed on January 3, 2014. A remarkable
increase in the number and size of white-matter hyperintensities can be observed (FLAIR sequence, D.a) compared with the scan of 17th of October. New
diffuse and rim gadolinium enhancing lesions are present (D.b).
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